Equity Research Database

Institutional Investment Pitches

Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.

Home Letters Funds Account

Ariel Small Cap Value Strategy's investment thesis on Haemonetics Corporation ($HAE) — Q2 2026 | Buyside Digest

All Pitches

View Letter Analysis

$HAENYSEHaemonetics Corporation

NEUTRAL

Ariel Small Cap Value Strategy—HAE

Fund Letter

Q2 2026

Published July 17, 2026

View Fund Profile

$85.28USD

-17.1% vs last month

$78.78Pitched

+8.2% since pitch

Market Cap$3.9B

P/E (TTM)N/A

52-Wk RangeN/A

Div. YieldN/A

Technical Chart

From the Fund Letter

Ariel Small Cap Value returned 17.04% net in Q2 2026, matching the Russell 2000 Value Index as U.S. equities rebounded sharply with their strongest quarterly gains since 2020. The portfolio benefited...

— Ariel Investments, LLC

BSD Research Exclusive

Unlock Full Institutional Investment Theses

Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.

6,000+ Institutional Pitches

Proprietary AI Analysis

100 Letter Unlocks/Cycle

SUBSCRIBE TO BSD RESEARCH ($55/MO)Compare All Plans

Already a Research or Pro subscriber? Sign In

◆ Keep Reading

What other investors think about $HAE, and what else Ariel Small Cap Value Strategy is buying.

Other pitches on $HAE

Other investors who've written on Haemonetics Corporation

No other institutional pitches found for this ticker yet.

View all $HAE pitches →